Article Archives

The Evolving Role of AI in Medical Research

A recent Medscape report revealed that 24% of respondents use AI tools to analyze medical literature and data. While these AI tools can help organize data and generate content, they

FDA Approves Vtama for Atopic Dermatitis for Patients Two Years and Above

Organon has announced the recent approval of Vtama ® (tapinarof) cream 1% for atopic dermatitis (AD) in adults and children aged 2 years and older. Vtama, an aryl hydrocarbon receptor agonist,

Study Finds Ultraprocessed Foods Linked to Active Psoriasis

Diet, which plays a critical role in reducing inflammation and improving quality of life, has emerged as a significant factor in managing inflammatory diseases. Concerns, however, continue to mount over

Study Highlights Safety and Efficacy of Monopolar Radiofrequency and HIFES in Patients Receiving Botulinum Toxin

A recent study published in the Journal of Drugs in Dermatology evaluated the safety and efficacy of a novel device combining monopolar radiofrequency (RF) and high-intensity facial electrical stimulation (HIFES)

FDA Approves BIMZELX for Moderate-to-Severe Hidradenitis Suppurativa

UCB recently announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX ® (bimekizumab-bkzx) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults. This approval is significant

New Protection and Repair Skincare Regimen Improves Photoaging

A recent study published in the Journal of Drugs in Dermatology has highlighted a six-step skincare regimen that improves signs of photoaging. This skincare regimen, called Essential Six (RATIONALE), includes

Study Evaluates Relationship Between Hidradenitis Suppurativa and Precocious Puberty

A recent study published in JAMA Dermatology has evaluated the relationship between precocious puberty and hidradenitis suppurativa (HS) in pediatric patients. Drawing on data from the Explorys databases, the study

FDA Grants Rare Pediatric Disease Designation for BPGbio’s BPM31510T for EB

The U.S. Food and Drug Administration (FDA) has granted BPGbio a Rare Pediatric Disease Designation for BPM31510T, its investigational treatment for epidermolysis bullosa (EB). This news brings hope to the EB

Study Finds Newly Diagnosed Alopecia Areata Linked to Increased Risk of Psychiatric and Autoimmune Conditions

A recent study published in the Journal of the American Medical Association (JAMA Dermatology) found that patients with newly diagnosed alopecia areata (AA) have a higher prevalence and incidence of

FDA Approves BOTOX® Cosmetic for Platysma Bands in Adults

Allergan Aesthetics has announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands connecting the jaw and neck

Topical Corticosteroid Phobia is Prevalent Among Patients with Chronic Hand Eczema

A study conducted in patients with chronic hand eczema (CHE) revealed that topical corticosteroid (TCS) phobia is a great concern, with many fearing future health risks associated with this type

Study Underway to Evaluate Rezpegaldesleukin (REZPEG) for the Treatment of Alopecia Areata

A new phase 2b study is currently underway to evaluate rezpegaldesleukin (REZPEG), an interleukin-2 receptor pathway agonist, for the treatment of severe to very severe alopecia areata (AA). This comes after REZPEG showed

Semaglutide Demonstrates Potential in Improving Outcomes for Hidradenitis Suppurativa in Patients with Obesity

In a study recently presented at the European Academy of Dermatology and Venerology (EADV) Congress 2024, it was revealed that semaglutide has the potential to treat hidradenitis suppurative (HS) in

Arcutis Announces FDA has Accepted its Supplemental New Drug Application for ZORYVE® (roflumilast) Foam

In a press release from Arcutis Biotherapeutics, Inc., they have announced that the U.S. Food and Drug Administration (FDA) has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for the

Eli Lilly’s EBGLYSS Receives FDA Approval for Patients 12 and Above with Moderate-to-Severe Atopic Dermatitis

Eli Lilly has announced that EBGLYSS ™ (lebrikizumab-lbkz) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis in adults and children

AHEAD Recommendations for Atopic Dermatitis

A team of expert dermatologists recently drafted recommendations for managing atopic dermatitis (AD) to optimize treatment outcomes. They noted that current treat-to-target recommendations for AD “may not include high enough

National Psoriasis Foundation Publishes Psoriasis Health Indicator Report

The National Psoriasis Foundation has released a Psoriasis Health Indicator Report detailing the health impacts of psoriasis. The report includes information and data on psoriasis, its health outcomes, prevention of

FDA Warns Consumers Against Using Chemical Peel Products Without Professional Consultation

The U.S. Food and Drug Administration (FDA) has warned consumers against the purchase and use of certain chemical peel skin products without first consulting a professional due to the risk

FDA Approves Galderma’s Nemluvio® (nemolizumab) for Prurigo Nodularis in Adults

The U.S. Food and Drug Administration (FDA) has approved Galderma’s Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of prurigo nodularis in adults. The FDA had previously

Skin Deep: Dr. Zoe Diana Draelos Explores Ethnic Variations in Skin Physiology – Dermatology Times Exclusive

In a recent article published in the Dermatology Times, Zoe Diana Draelos, MD, addressed some of the complex issues surrounding the physiologic differences in skin across various ethnic groups. Dr.

LivDerm Articles

Latest Articles

Explore Articles